cas 1449598-86-0|| where to buy 2-Chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

Nom du produit:2-Chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

IUPAC Name:2-chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

Unité d'emballage	Stock disponible	Prix($)
CM337294-1g	in stock	ƴȅƴ
CM337294-10g	in stock	ƚŞŞŸ
CM337294-100g	in stock	ȖȯȖŸ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1449598-86-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1449598-86-0; Formule moléculaire:C8H4ClFN2O; Point de fusion:-; Code SMILES:O=C1C=C(Cl)N=C2N1C=C(F)C=C2; Densité:

: Numéro de catalogue:CM337294; Poids moléculaire:198.58; Point d'ébullition:; N° Mdl:MFCD28659052; Stockage:

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.